Marker Therapeutics Inc.

09/13/2022 | Press release | Distributed by Public on 09/13/2022 07:17

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML - Form 8-K